|
US6051397A
(en)
|
1993-11-16 |
2000-04-18 |
Max Planck Gesellschaft Zur Forderung Der Wissenschaften |
DNA encoding MCK-10, a novel receptor tyrosine kinase
|
|
US20020115173A1
(en)
|
2000-12-11 |
2002-08-22 |
Children's Medical Center Corporation |
Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity
|
|
US7855076B2
(en)
|
2002-03-12 |
2010-12-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Use of discoidin domain receptor 1 (DDR1) and agents that affect the DDR1/collagen pathway
|
|
WO2003085125A1
(en)
|
2002-04-03 |
2003-10-16 |
Agy Therapeutics, Inc. |
Use of biomolecular targets in the treatment and visualization of brain tumors
|
|
US20070025997A1
(en)
|
2002-04-03 |
2007-02-01 |
Usha Nagavarapu |
Use of biomolecular targets in the treatment and visualization of brain tumors
|
|
US20100166731A1
(en)
|
2005-09-30 |
2010-07-01 |
Bartz Steven R |
Methods and Compositions for Treating Cancer
|
|
EP1992347A1
(en)
|
2007-05-18 |
2008-11-19 |
Cellzome Ag |
Treatment of DDR1 positive cancer using imatinib
|
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
|
CA2780221A1
(en)
|
2009-11-04 |
2011-05-12 |
Fabrus Llc |
Methods for affinity maturation-based antibody optimization
|
|
AU2011295968B2
(en)
|
2010-09-01 |
2017-01-05 |
Biogen Ma Inc. |
Rapid generation of anti-idiotypic antibodies
|
|
WO2012085064A1
(en)
|
2010-12-23 |
2012-06-28 |
Roche Diagnostics Gmbh |
Detection of a posttranslationally modified polypeptide by a bi-valent binding agent
|
|
MX2013011363A
(es)
*
|
2011-04-01 |
2014-04-25 |
Sloan Kettering Inst Cancer |
Anticuerpos para peptidos citosolicos.
|
|
US9550835B2
(en)
*
|
2011-08-23 |
2017-01-24 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-DDR1 antibody having anti-tumor activity
|
|
GB201115529D0
(en)
*
|
2011-09-08 |
2011-10-26 |
Imp Innovations Ltd |
Antibodies, uses and methods
|
|
US10633451B2
(en)
|
2012-02-03 |
2020-04-28 |
Hoffmann-La Roche Inc. |
Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
|
|
HK1204926A1
(en)
|
2012-02-29 |
2015-12-11 |
吉联亚生物科技有限公司 |
Antibodies to matrix metalloproteinase 9
|
|
US11873281B2
(en)
|
2012-07-12 |
2024-01-16 |
Hangzhou Dac Biotech Co., Ltd. |
Conjugates of cell binding molecules with cytotoxic agents
|
|
US20140086913A1
(en)
|
2012-09-24 |
2014-03-27 |
Gilead Sciences, Inc. |
Anti-ddr1 antibodies
|
|
WO2014047624A1
(en)
*
|
2012-09-24 |
2014-03-27 |
Gilead Sciences, Inc. |
Anti-ddr1 antibodies
|
|
WO2014140330A1
(en)
|
2013-03-15 |
2014-09-18 |
Oryzon Genomics, S.A. |
Anti-ddr1 internalizing antibodies and their medical use
|
|
KR102113310B1
(ko)
|
2013-09-03 |
2020-05-20 |
아주대학교 산학협력단 |
암 세포 분리용 조성물, 키트 및 이를 이용한 분리 방법
|
|
CN115160441A
(zh)
|
2013-09-26 |
2022-10-11 |
埃博灵克斯股份有限公司 |
双特异性纳米抗体
|
|
WO2015081127A2
(en)
|
2013-11-26 |
2015-06-04 |
Gilead Sciences, Inc. |
Therapies for treating myeloproliferative disorders
|
|
US20170158762A1
(en)
*
|
2014-01-30 |
2017-06-08 |
Anaptysbio, Inc. |
Antibodies directed against discoidin domain receptor family, member 1 (ddr1)
|
|
IL252192B2
(en)
|
2014-11-10 |
2024-03-01 |
Del Mar Pharmaceuticals |
Dianhydrogalactitol together with radiation to treat non-small-cell carcinoma of the lung and glioblastoma multiforme
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
AU2017228371A1
(en)
|
2016-03-04 |
2018-09-13 |
Gilead Sciences, Inc. |
Compositions and combinations of autotaxin inhibitors
|
|
KR20180007924A
(ko)
|
2016-07-14 |
2018-01-24 |
주식회사 코리아하이텍 |
차량용 빔프로젝터 방열 장치
|
|
US20190310250A1
(en)
*
|
2016-12-16 |
2019-10-10 |
Merck Patent Gmbh |
Methods for the use of galectin 3 binding protein detected in the urine for monitoring the severity and progression of lupus nephritis
|
|
CA3047593A1
(en)
*
|
2017-01-02 |
2018-07-05 |
The Board Of Regents Of The University Of Texas System |
Anti-lair1 antibodies and their uses
|
|
CA3055256A1
(en)
*
|
2017-03-09 |
2018-09-13 |
Mab Discovery Gmbh |
Antibodies specifically binding to human il-1r7
|
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
KR20210122319A
(ko)
|
2017-04-06 |
2021-10-08 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
비스-링키지를 사용한 세포독성 약물의 접합
|
|
KR20200007905A
(ko)
|
2017-05-18 |
2020-01-22 |
리제너론 파마슈티칼스 인코포레이티드 |
사이클로덱스트린 단백질 약물 접합체
|
|
WO2018237287A1
(en)
*
|
2017-06-22 |
2018-12-27 |
Apexigen, Inc. |
Anti-vista antibodies and methods of use
|
|
EP3655961A4
(en)
|
2017-07-17 |
2021-09-01 |
Massachusetts Institute of Technology |
HEALTHY AND SICK BARRIER TISSUE CELL ATLAS
|
|
MX2020004691A
(es)
|
2017-11-07 |
2020-08-20 |
Regeneron Pharma |
Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
|
|
EP3621652A4
(en)
|
2017-12-31 |
2021-01-13 |
Hangzhou DAC Biotech Co, Ltd |
CONJUGATE OF ANALOGUE OF TUBULYSIN WITH BRANCHED LINKS
|
|
WO2019243431A1
(en)
|
2018-06-20 |
2019-12-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating melanoma
|
|
EA202190189A1
(ru)
|
2018-07-05 |
2021-04-16 |
Ханчжоу Дэк Биотек Ко., Лтд |
Сшитое производное димера пирролобензодиазепина (pbd) и его конъюгаты
|
|
WO2020046770A1
(en)
|
2018-08-31 |
2020-03-05 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Kinase activity in tumors
|
|
IL282182B2
(en)
|
2018-10-12 |
2025-09-01 |
Hangzhou Dac Biotech Co Ltd |
Cytotoxic drug conjugates with a bis linkage
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
CA3128264A1
(en)
|
2019-01-31 |
2020-08-06 |
Hangzhou Dac Biotech Co., Ltd |
A conjugate of an amanita toxin with branched linkers
|
|
PH12021500050A1
(en)
|
2019-06-24 |
2022-05-02 |
Hangzhou Dac Biotech Co Ltd |
A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers
|
|
CN114040781A
(zh)
|
2019-06-24 |
2022-02-11 |
杭州多禧生物科技有限公司 |
Tubulysin衍生物与细胞结合分子偶联物的制剂配方
|
|
WO2021011634A1
(en)
|
2019-07-15 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
KR20210053252A
(ko)
|
2019-11-01 |
2021-05-11 |
(주)셀레메디 |
면역 관문 분자와 결합 가능한 분자가 융합된 단백질 및 이의 용도
|
|
WO2021086159A1
(ko)
|
2019-11-01 |
2021-05-06 |
(주)셀레메디 |
면역 관문 분자와 결합 가능한 분자가 융합된 단백질 및 이의 용도
|
|
CN115443150A
(zh)
*
|
2019-12-17 |
2022-12-06 |
德克萨斯大学系统董事会 |
新型ddr1抗体和其用途
|
|
AU2021225870A1
(en)
|
2020-02-27 |
2022-10-20 |
Janssen Biotech, Inc. |
Materials and methods for modulating an immune response
|
|
US20210284731A1
(en)
|
2020-03-13 |
2021-09-16 |
Janssen Biotech, Inc. |
Methods and materials for modulating an immune response
|
|
BR112022025583A2
(pt)
|
2020-06-19 |
2023-01-03 |
Hangzhou Dac Biotech Co Ltd |
Conjugado de molécula de ligação à superfície celular e análogo de camptotecina, composto conjugável, célula de tumor, composição farmacêutica, agente quimioterapêutico, e, agentes sinergísticos
|
|
CN116723839A
(zh)
|
2020-10-14 |
2023-09-08 |
C4医药公司 |
用于降解靶蛋白质的三环杂双官能化合物
|
|
WO2022092974A1
(ko)
|
2020-10-30 |
2022-05-05 |
(주)셀레메디 |
항체 유사 단백질 및 그 용도
|
|
WO2022135332A1
(zh)
|
2020-12-21 |
2022-06-30 |
映恩生物制药（苏州）有限公司 |
一种甾体偶联物
|
|
CN114807042B
(zh)
|
2021-01-22 |
2024-09-03 |
南京助天中科科技发展有限公司 |
一种嵌合抗原受体改造的nk细胞及其制备方法与应用
|
|
WO2022171101A1
(zh)
|
2021-02-10 |
2022-08-18 |
映恩生物制药（苏州）有限公司 |
一种甾体偶联物
|
|
NL2028075B1
(en)
|
2021-04-26 |
2022-11-03 |
Alphathera Ag |
Targeting system for cancer comprising a radioisotope
|
|
WO2022235059A1
(ko)
|
2021-05-03 |
2022-11-10 |
(주)셀레메디 |
폐암의 예방 또는 치료용 약학 조성물
|
|
JP2024524301A
(ja)
|
2021-07-02 |
2024-07-05 |
ラエクナ セラピューティクス シャンハイ カンパニー リミテッド |
活性化肝星細胞（ｈｓｃ）の枯渇及びその使用
|
|
CN120463762A
(zh)
|
2021-08-26 |
2025-08-12 |
映恩生物科技(上海)有限公司 |
一种甾体化合物及其缀合物
|
|
US20250179114A1
(en)
|
2021-09-14 |
2025-06-05 |
Duality Biologics (Suzhou) Co., Ltd. |
Anti-Inflammatory Compound and Use Thereof
|
|
EP4405487A4
(en)
|
2021-09-26 |
2025-12-03 |
Wuxi Biologics Ireland Ltd |
IL-2 VARIANTS AND THEIR FUSING PROTEINS
|
|
WO2023061478A1
(zh)
|
2021-10-15 |
2023-04-20 |
先声再明医药有限公司 |
三环类化合物
|
|
EP4426727A2
(en)
|
2021-11-03 |
2024-09-11 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
WO2023163873A1
(en)
|
2022-02-23 |
2023-08-31 |
Mayo Foundation For Medical Education And Research |
Synergistic drug combinations to treat cancer
|
|
JP2025507733A
(ja)
|
2022-02-28 |
2025-03-21 |
ウーシー バイオロジクス アイルランド リミテッド |
Ｉｌ－１５変異体を含むヘテロ二量体ポリペプチド錯体とその使用
|